Mr. Ibrahem/Etravirine
Clinical data
Trade namesIntelence
Other namesTMC125
AHFS/Drugs.comMonograph
MedlinePlusa608016
License data
Pregnancy
category
  • AU: B1
Routes of
administration
By mouth
Drug classNNRTI[1]
Legal status
Legal status
Pharmacokinetic data
Protein binding99.9%
MetabolismLiver (CYP3A4, CYP2C9 & CYP2C19-mediated)
Elimination half-life41±20 hours
ExcretionFaeces (93.7%), urine (1.2%)
Identifiers
  • 4-[6-Amino-5-bromo-2-[(4-cyanophenyl)amino] pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile
Chemical and physical data
FormulaC20H15BrN6O
Molar mass435.285 g·mol−1
3D model (JSmol)
  • N#Cc3cc(c(Oc1nc(nc(c1Br)N)Nc2ccc(C#N)cc2)c(c3)C)C
  • InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27) checkY
  • Key:PYGWGZALEOIKDF-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Etravirine (ETR) sold under the brand name Intelence, is a medication used to treat and prevent HIV/AIDS.[2] It is used in people who have been previously treated, together with other antiretroviral medications.[1][4] It is taken by mouth twice per day.[2]

Common side effects include rash, diarrhea, nausea, peripheral nerve problems, and headache.[1][2] Other side effects may include Stevens-Johnson syndrome, immune reconstitution syndrome, and lipodystrophy.[2] Safety in pregnancy is unclear.[2] It is a non-nucleoside reverse transcriptase inhibitor (NNRTI), which blocks reverse transcriptase.[1]

Etravirine was approved for medical use in the Canada, Europe, and the United States in 2008.[2][5][1] It is available as a generic medication.[6] In the United Kingdom a month of treatment costs the NHS about £300 as of 2021.[3] This amount in the United States costs about 380 USD.[6]

References

edit
  1. ^ a b c d e f "Intelence". Archived from the original on 18 November 2021. Retrieved 16 December 2021.
  2. ^ a b c d e f g h "Etravirine Monograph for Professionals". Drugs.com. Archived from the original on 31 July 2020. Retrieved 16 December 2021.
  3. ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 684. ISBN 978-0857114105.
  4. ^ "Etravirine" (PDF). March 2009. Archived (PDF) from the original on 15 April 2021. Retrieved 16 December 2021.
  5. ^ "Newsletter July 2008". pmprb-cepmb.gc.ca. 20 June 2014. Archived from the original on 18 October 2020. Retrieved 16 December 2021.
  6. ^ a b "Etravirine Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 5 November 2016. Retrieved 16 December 2021.